VEGFA and angiosarcoma: Considering the origin of angiosarcoma cells, attention is now focusing on anti-angiogenic therapy, such as the anti-vascular endothelial growth factor A (VEGFA) monoclonal antibody bevacizumab and the broad-spectrum tyrosine-kinase inhibitors sorafenib and pazopanib, which target vascular endothelial growth factor receptors (VEGFRs).